Biosimilars: Key regulatory considerations and similarity assessment tools.

about

Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q55283747-0C9EE14D-5A63-456F-9777-056D6F656B4E

P2860

Biosimilars: Key regulatory considerations and similarity assessment tools.

Item

http://www.wikidata.org/entity/Q46729332

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Biosimilars: Key regulatory considerations and similarity assessment tools.

@en

Biosimilars: Key regulatory considerations and similarity assessment tools.

@nl

type

Item

label

Biosimilars: Key regulatory considerations and similarity assessment tools.

@en

Biosimilars: Key regulatory considerations and similarity assessment tools.

@nl

prefLabel

Biosimilars: Key regulatory considerations and similarity assessment tools.

@en

Biosimilars: Key regulatory considerations and similarity assessment tools.

@nl

P1476

Biosimilars: Key regulatory considerations and similarity assessment tools.

@en

P2093

Anne M Ryan

http://www.w3.org/2001/XMLSchema#string

Arindam Bose

http://www.w3.org/2001/XMLSchema#string

Carol F Kirchhoff

http://www.w3.org/2001/XMLSchema#string

Hugh D Conlon

http://www.w3.org/2001/XMLSchema#string

Scott Anderson

http://www.w3.org/2001/XMLSchema#string

Xiao-Zhuo Michelle Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Development of biosimilars in an era of oncologic drug shortages

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies

Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequentia

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.

Immunogenicity of therapeutic monoclonal antibodies.

Key strategic factors for stakeholders in the current global biosimilar market.

Physicochemical characterization of Remsima.

A practical guide about biosimilar data for health care providers treating inflammatory diseases

P304

2696-2705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1002/BIT.26438

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28842986

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

5698755

http://www.w3.org/2001/XMLSchema#string

Biosimilars: Key regulatory considerations and similarity assessment tools.

about

P2860

P2860

Biosimilars: Key regulatory considerations and similarity assessment tools.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932